ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Eli Lilly & Co. has agreed to acquire Alnara, a privately held biotechnology company that develops protein therapeutics to treat metabolic diseases. “The acquisition of Alnara provides Lilly with a promising entry into enzyme replacement therapy,” says Bryce Carmine, president of Lilly BioMedicines. Alnara’s lead product, liprotamase, is a pancreatic enzyme replacement therapy that is under FDA review for the treatment of exocrine pancreatic insufficiency, a condition associated with cystic fibrosis and chronic pancreatitis.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X